Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Ceases Oral Copaxone Development

This article was originally published in The Pink Sheet Daily

Executive Summary

The company said it is still considering development of “various non-parenteral formulations” for the MS therapy.
Advertisement

Related Content

Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
Teva To Investigate High-Dose Copaxone
Teva To Investigate High-Dose Copaxone
Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years
Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years
Copaxone Growth Helps Teva Offset Declining Generics Business
Copaxone Growth Helps Teva Offset Declining Generics Business

Topics

Advertisement
UsernamePublicRestriction

Register

PS063884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel